tbuckley/cabot-search huggingface dataset:
Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer
Authors: A. Ardavanis, P. Kountourakis, I. Mantzaris, S. Malliou, D. Doufexis, D. Sykoutri, M. Thomopoulos, I. Fragos, G. Rigatos
Journal: Journal of Clinical Oncology (2008)

15085 Background: Bevacizumab (BEV), a recombinant humanized monoclonal antibody against VEGF, is approved for intravenous administration in combination with standard chemotherapy (CT) regimens for advanced colorectal cancer (CRC); few data exist regarding the efficacy of BEV administered together with capecitabine (CAP) and irinotecan (IRI) (XELIRI). This study was conducted to investigate the safety and efficacy profile of the BEV/XELIRI regimen. Methods: Adult patients 18 years or older with advanced colorectal cancer, ECOG PS ≤2, exposed to ≤ 1 chemotherapy (CT) regimen not including IRI or CAP, had to receive BEV 7.5 mg/kg and IRI 220 mg/m2 both on day 1; CAP 1.8g/m2/d, d1–14. Treatment was repeated every 21 days up to a total of 8 cycles. Responding or stabilized patients had to be treated with BEV 7.5 mg/m2, administered as maintenance every 21 days until disease progression. Results: Thirty four patients were treated, the majority (29/85.3%) in first line; eighteen (53%) male, 16 (47%) female, aged 37–83 (median 69.5 years). Treatment was moderately tolerated with mainly gastrointestinal complications; haematological, cardiovascular and other toxicities were also recorded, but they were manageable. Overall RR was 47.1%, while 41.2% of patients achieved stable disease. Median PFS and OS were 8 (95% CI, 6.3 - 9.7) and 14 (95% CI, 11.5- 16.5) months, respectively with 16% progression-free and 62% alive at 12 months. Conclusions: The combination of BEV with XELIRI is a novel regimen with interesting activity and acceptable tolerability in advanced CRC, desserving further investigation by larger prospective studies comparing it with other BEV-containing and/or other regimens. No significant financial relationships to disclose.
Erlotinib for metastatic non-small cell lung cancer (mNSCLC): First, second or third line setting—Does it matter? A single institution experience
Authors: S. Ailawadhi, L. Derby, R. Natrajan, M. E. Reid, N. Ramnath
Journal: Journal of Clinical Oncology (2008)

19083 Background: Erlotinib is approved for the treatment of refractory metastatic non-small cell lung cancer (mNSCLC). Studies to define who might benefit maximally from erlotinib have been inconclusive. We analyzed practice patterns and outcomes related to use of erlotinib for mNSCLC in a comprehensive cancer center. Methods: All patients with mNSCLC who received single agent erlotinib between 12/01/04 & 12/31/06 were included. Descriptive analyses & Kaplan-Meier survival curves for selected variables were generated. Results: Of 116 patients, there were 73 females (F) & 43 males (M). Median age was 66 years (range 38–87). Histology was adeno (50%), large cell (1%), squamous cell (25%) & poorly differentiated carcinoma (24%). Most (68%) had de novo stage IIIB/IV, 32% had recurrent/progressive disease after initial diagnosis of stage I-III NSCLC. Majority (93%) were smokers. ECOG status was 0 (4%), 1 (47%), 2 (44%) & 3 (5%). Erlotinib was administered as 1st (27%), 2nd (45%), 3rd (25%) or 5th line (3%) therapy. Median dose was 150mg (range 100–150 mg) p.o daily. Median treatment duration was 8 weeks (range 1–72). Response data was available for 100 patients (86%). Stable disease (SD) was seen in 22 [9 M, 13 F; 1 non-smoker (NS), 22 smokers (S)], partial response in 1 (F, NS) & progressive disease (PD) in 77 (27 M, 50 F; 5 NS, 72 S). Median overall survival (OS) was 16 months. Median OS from the date of erlotinib initiation was 5.4 months. There was a significant difference in OS by initial disease (recurrent versus de novo IIIB/IV) (p=0.0034; Log Rank). There was no significant difference in OS when stratified for timing (1st, 2nd, 3rd line etc) (p=0.724; Log Rank) or dose (100 mg versus 150mg) (p=0.702; Log Rank). There was no significant association between response and gender (p=0.81; Fisher’s Exact) or smoking status (p=0.66; Fisher’s Exact). Conclusions: Majority of patients received single agent erlotinib for mNSCLC in the second or third line setting. We found a statistically significant difference in OS to erlotinib in patients who presented with recurrent disease versus those with de novo mNSCLC. There was no difference in OS based on the different initial dosages or whether erlotinib was used in 1st, 2nd or 3rd line settings. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Oncology
Phase I trial of anti-PSMA designer T cells in advanced prostate cancer.
Authors: R. P. Junghans, R. Rathore, Q. Ma, R. Davies, A. Bais, E. Gomes, E. Beaudoin, P. Davol, M. Abedi, S. Cohen
Journal: Journal of Clinical Oncology (2011)

130 Background: We created chimeric immunoglobulin-T cell receptors (IgTCR) specific for prostate specific membrane antigen (PSMA). When expressed in patient T cells, these “designer T cells” (dTc) specifically kill prostate cancer cells in vitro and in vivo in animal models, with 5/9 (55%) of xenografted mice experiencing complete remissions (Ma et al. Prostate 2004:61:12–25). A phase I clinical trial was approved by the FDA. Methods: Patient T cells are retrovirally transduced and expanded ex vivo to span dose levels of 10^9 to 10^11 T cells. Patients undergo prior non-myeloablative (NMA) conditioning to create “hematologic space” into which designer T cells are infused for stable engraftment and prolonged in vivo efficacy. Patients are co-administered continuous infusion IL2. Outcomes include Phase Ia goals of safety and Phase Ib goals of establishing an optimal biologic dose in terms of designer T cell engraftment. Results: Five patients have been treated, three at 10^9 and two at 10^10 cell dose levels. Excellent T cell modifications of 30%-60% were obtained. After NMA conditioning, T cells were infused. Stable engraftments of 1%-20% post-recovery at one month after T cell infusion, thus affirming one of the study end-points. Patients experienced neutropenic fever after conditioning, but no designer T cell-related toxicities. Two patients had partial responses with PSA reductions of 50 and 70% in the two months following treatment with projected benefits of 4 months gain of time to return to starting PSA levels. Results will be updated at the conference. Conclusions: A new approach to adoptive immune therapy in metastatic prostate cancer has been devised with encouraging early results. Patients are being actively recruited. This clinical trial received partial funding from the US Army/DOD. Preclinical work was supported by the Prostate Cancer Foundation. No significant financial relationships to disclose.
General Recommendations on Immunization
Journal: Annals of Internal Medicine (1983)

Diagnosis and Treatment1 May 1983General Recommendations on ImmunizationRecommendation of the Immunization Practices Advisory CommitteeAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-5-615 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractThis revision of the "General Recommendations on Immunization" updates the 1980 statement. Changes from that statement clarify information on possible interference with the immune response by spacing immunobiologic agents. Recommendations for vaccinating persons with allergies are revised. New sections dealing with many aspects of immunization procedures have been added. This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: ▸From the Immunization Practices Advisory Committee, Centers for Disease Control; Atlanta, Georgia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byACUTE HEPATIC FAILURE IN HEPATITIS AAcceptance of Hepatitis B Vaccine Among Dental Health Care WorkersImmune response to anti-HBV vaccination: Study of conditioning factorsPrevalence of hepatitis B markers in outpatiens of a chemotherapy-oncology clinicAcceptance of hepatitis B vaccine among hospital workers. 1 May 1983Volume 98, Issue 5_Part_1Page: 615-622KeywordsAllergy and immunologyImmune response Issue Published: 1 May 1983 PDF downloadLoading ...
Osteosarcoma in children aged less than five years at diagnosis: Experience of the Cooperative Osteosarcoma Study Group
Authors: L. Kager, A. Zoubek, M. Kevric, M. Dominkus, S. Lang, U. G. Exner, R. Mass, H. Jürgens, S. Bielack
Journal: Journal of Clinical Oncology (2007)

9554 Background: The incidence of osteosarcoma considerably varies with age and preschool children are reported to be extremely rarely affected. This study was conducted to investigate presentation, treatment, and outcome in very young children with osteosarcoma. Patients and Methods: The authors retrospectively analyzed the collected data of 2,706 consecutive patients with newly diagnosed high-grade osteosacroma of bone registered in the COSS studies between 1976 and 2005; and identified 28 patients (1%) aged less than five years at diagnosis. Demographic, diagnostic, tumor, and treatment related variables; response and survival data of these 28 patients were analyzed. Results: Of the 28 (male, N = 16; female, N = 12) identified toddlers (two years, N = 4; three years, N = 10; four years, N = 14), 27 presented with a high-grade central osteosarcoma of an extremity (femur, N = 12; humerus, N = 10; tibia, N = 5) and one with a secondary osteosarcoma of the orbit. The size of the primary extremity tumor was large in 74% of patients. Primary metastases were detected in 4/28 children. All 28 patients received multiagent chemotherapy, and 13 of the 21 analyzed tumors responded well to neoadjuvant chemotherapy (&gt;90% necrosis). Limb sparing surgery was feasible in 11 children, whereas ablative procedures were performed in 14 patients. A macroscopically complete surgical remission of all clinically detectable tumors was achieved in 24/28 patients during front line therapy. With a median follow-up of 1.7 years (4.2 years for survivors), 15/28 patients were alive. Outcome was poorer for the 28 toddlers compared to the 2,678 older patients (5-year event free survival 43% ± 10% vs. 56% ± 1%)(P = 0.02). Conclusion: Osteosarcoma is extremely rare in preschool children. These young patients often have large tumors which may require mutilating resections. Despite the high rate of ablative surgery, the prognosis, however, may be poorer compared to older patients. No significant financial relationships to disclose.
Retrospective analysis of resected primary colorectal cancer revealed
Authors: K. H. Khan
Journal: Journal of Clinical Oncology (2009)

e15137 Background: Lymphadenectomy in colorectal cancer is believed to be a critical component concerning prognosis and survival of patients.. The aim of this study was to analyze the relationship between the number of lymph nodes harvested (LNH) and the number of lymph nodes involved (LNI), at the histological examination of the specimens of resected primary colorectal cancer (CRC) at our unit. Results: Over the five-year study period, 142 resections for primary CRC were performed on 141 patients (one metachronous). Mean number of resections per annum was 28. There were 86 (60.5%) colonic and 56 (39.5%) rectal cancers (Fig 1). There were 70 (49.3%) anterior resections (Fig 2). M:F ratio was 0.97:1. Median age was 71years for colonic and 69.5years for rectal cancers. Eighty eight percent of resections were elective (OR=2.2 RR=1.14 p=0.003 compared to the national audit) 1 . Adenocarcinoma NOS constituted 94% of all histology results (5% mucinous and 1% signet ring). Median CRM was 7.5mm (mean=8.8mm) (fig 3). The CRM involvement was 12.7% for all CRC and 16% for rectal cancers. The LRM involvement was 1.5%. Median overall LNH was 12, (mean=13 p=0.08 when compared to the recommended LNH of 12) (Fig 5). Median LNH for rectal cancers=11 and for colonic cancer=13. There were 11 (14%) APRs compared to 70 (86%) sphincter-saving operations from a total of 83 rectal resections. 84%of resections were R 0 . The 30-day all-cause mortality was 4.3%. Actuarial survival curve demonstrated 17.6% chance of metastasis at presentation, all-stage 3-year disease-free survival (DFS) of 67% and of 82% for stages I-III (T any N any M 0 ). CEA relapse as a marker of disease recurrence (available for n=125) revealed 3-year DFS=71%.When correlation was determined between LNH and lymph node involvement, it revealed a low correlation (r=0.159 p=0.06) which was statistically insignificant. When the national audit calculated the same relationship among its much larger sample the results were the same (r=0.152 p=0.001) 3 and had achieved statistical significance. Conclusions: LNI as a function of tumour and host behaviour is of prognostic significance whereas LNH may be a marker of ‘pathologist's diligence’ at the histological examination and therefore a quality assurance (QA) tool. No significant financial relationships to disclose.
NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.
Authors: Daniel Ma, Evanthia Galanis, David Schiff, Wenting Wu, Patrick J. Peller, Caterina Giannini, Paul D. Brown, Joon H. Uhm, Steven McGraw, Kurt A. Jaeckle, Patrick J. Flynn, Jan C. Buckner, Jann Nagina Sarkaria
Journal: Journal of Clinical Oncology (2012)

2031 Background: The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt pathway as a critical modulator of cell survival. Preclinical studies in GBM indicate that the combination of mTOR inhibitors, such as everolimus (RAD001), with either radiation therapy (RT) or temozolomide (TMZ) provide increased tumor cell killing. Methods: Newly diagnosed GBM pts were eligible for the study. RAD001 was dosed orally at 70 mg/week weekly, starting 1 week prior to RT/TMZ, and continued throughout RT/TMZ, adjuvant TMZ and then until progression. This was a single arm phase II design powered to detect a true overall survival at 12 months (OS12) of 73% (vs 58% in historical controls). Secondary endpoints were toxicity, response rate, and time to progression (TTP). A subgroup of patients with measurable residual disease were eligible for the PET imaging component of the study, consisting of an 18 FLT-PET/CT scan performed before and after the initial two doses of RAD001 but before the first dose of RT or TMZ. Results: 103 patients were accrued to phase II of which 100 were evaluable. The median age was 60.5 years (23-81), median ECOG PS was 1, 46 patients had GTR, 33 STR, and the remainder had biopsy at diagnosis. Treatment tolerance was acceptable: 17% patient had at least one grade 3 hematologic toxicity; 14% had at least one grade 4 hematologic toxicity, 42% had at least one grade 3 non-heme toxicity, while 12% had at least one grade 4 non-heme toxicity. No increased incidence of infectious complications was observed and there were no treatment related deaths. Median PFS was 5.3 months (1.3-21.4), with 22 patients progression free. Mature OS data will be available at the meeting. MGMT methylation status analysis is ongoing. Of the pts who had evaluable FLT-PET data, three of eight (37.5%) had a drop in SUVmax &gt;25% after two treatments of RAD001. Conclusions: RAD001 with standard of care chemoradiation had moderate toxicity. Serial 18 FLT-PET was feasible for evaluating drug-induced changes in tumor proliferation following RAD001. Final outcome data and association of MGMT status with outcome will be reported at the meeting.
Cancer-Related fatigue interferes with activities of daily living among 753 patients receiving chemotherapy: A URCC CCOP study
Authors: K. M. Mustian, O. Palesh, C. E. Heckler, J. A. Roscoe, G. R. Morrow, A. Jacobs, B. Issell, P. O. Schwartzenberger
Journal: Journal of Clinical Oncology (2008)

9500 Background: Cancer-related fatigue (CRF) is hypothesized to impair quality of life by interfering with patients' abilities to perform activities of daily living (ADL). The purpose of this study is to describe the interference of CRF with ADL, specifically performing household chores, cooking, bathing, dressing, working, socializing, engaging in sexual activity and running errands. Methods: 753 patients (M age = 57; N = 483 female) with mixed cancer diagnoses were assessed on CRF and its interference with ADL 7 days after their first 2 chemotherapy infusions as part of a large nationwide clinical trial conducted by the URCC CCOP Research Base. CRF and interference were assessed using questions from the Multidimensional Assessment of Fatigue instrument anchored with a 10-point Likert Scale (1 = "Not at all" to 10 = "A great deal"). Results: 553 of these 753 patients reported CRF at cycle 1 (M = 5.99; SE = 0.10) and cycle 2 (M = 5.73; SE = 0.09). In these 553 patients, CRF interfered with household chores in 488 patients (M = 4.89; SE = 0.12), cooking in 459 patients (M = 4.52; SE = 0.13), bathing in 545 patients (M = 4.21; SE = 0.14), dressing in 548 patients (M = 4.22; SE = 0.14), working in 322 patients (M = 4.46; SE = 0.18, socializing in 541 patients (M = 4.55; SE = 0.12), engaging in sexual activity in 368 patients (M = 4.64; SE = 0.12), and running errands in 513 patients (M = 4.59; SD = 0.13) at cycle 1. CRF interfered with household chores in 488 patients (M = 4.89; SE = 0.12), cooking in 459 patients (M = 4.52; SE = 0.13), bathing in 545 patients (M = 4.21; SE = 0.14), dressing in 548 patients (M = 4.22; SE = 0.14), working in 322 patients (M = 4.46; SE = 0.18), socializing in 541 patients (M = 4.55; SE = 0.12), engaging in sexual activity in 368 patients (M = 4.64; SE = 0.12), and running errands in 513 patients (M = 4.59; SD = 0.13) during cycle 2. CRF was significantly correlated with interference for all ADL at both cycle 1 and 2 (all p < 0.01). There were no significant differences on CRF interference with ADL between cycle 1 and 2. There were significant differences in CRF interference with ADL based on gender, race, diagnosis and adjuvant/metastatic therapy. Conclusions: CRF interferes with cancer patients' abilities to perform ADL while receiving chemotherapy. Funded by NCI grant U10 CA37420. No significant financial relationships to disclose.
Smoking cessation in long-term survivors of germ cell tumor (GCT)
Authors: M. Hentrich, M. Fegg, C. Jost, S. Meiler, A. Gerl
Journal: Journal of Clinical Oncology (2005)

4737 Background: Cigarette smoking is the most significant source of preventable morbidity and premature mortality in developed countries. As long-term survivors of GCT have been found to be at an increased risk of developing vascular events and second cancer, smoking cessation could be an important factor to improve health status and overall survival. The purpose of this study was to investigate the use of tobacco in patients after GCT therapy. Methods: 474 patients treated for GCT between 1979 and 2000 at the University of Munich were asked to complete a self-report questionnaire on psychosocial dimensions which included items on tobacco smoking before and after treatment of GCT. These data were compared with those on smoking habits in the general male population in Germany. Results: 341 of 474 patients (71.9%) returned a completed questionnaire. The median age of responding patients was 41.9 years at the time of the study and 31.2 years at the time of GCT diagnosis. The median follow-up period was 9.6 years. 114 of 341 patients (33.4%) reported to smoke at the time of the study. 108 were cigarette smokers with 67.7% smoking more than 10 cigarettes a day. With respect to different groups of age (< 20 years, 20 - 29 years, 30 - 39 years and 40 - 49 years), 33.3%, 37.7%, 36.1% and 18.2% reported to smoke. The corresponding percentages of smoking patients in the general male population are 27.9%, 43.3%, 45.5%, and 42.7%. After diagnosis and/or therapy of GCT 83.8% of smoking patients had changed their smoking behavior by either having reduced (20%), having temporarily stopped (28.1%) or having definitively stopped smoking (35.7%). Patients reduced or stopped smoking irrespective of tumor histology (seminoma vs nonseminoma; p=0.33), tumor stage (I vs. II vs III; p=0.47), whether they had received chemotherapy or not (p=0.89), and irrespective of the number of chemotherapy courses applied (p=0.88). With advancing age more patients tended to stop smoking. Conclusions: After diagnosis and treatment of GCT most patients changed their habit of tobacco smoking. This resulted in lower numbers of smoking patients as compared to the general male population in Germany. No significant financial relationships to disclose.
Study of the association between body mass index and "silent asthma"
Authors: Marianna Ribeiro, Guilhardo Ribeiro
Journal: European Respiratory Journal (2013)

Asthma is a chronic inflammatory disease of the airways, potentially reversible, multifactorial, characterized by bronchial hyperreactivity. This disease commonly manifested by wheezing, coughing and dyspnea causing a pulmonary obstruction, diagnosed by spirometry with proof-pharmacodynamics. Some patients with  not attend the typical clinical picture, being oligoassintomaticos or asymptomatic, which makes diagnosis of the disease. But are diagnosed by spirometry testing with pharmaco-dynamics, demonstrating a dissociation clinical spirometric x, then being considered carriers of the silent asthma.  Objectives: Join the silent asthma in normal weight, overweight and obese.  Methods: We evaluated 156 patients in outpatient endocrinology, 63 patients from the University Hospital Professor Edgar Santos and 93 patients from a private clinic. All patients were asymptomatic respiratory historico without asthma, allergic rhinitis, diabetes mellitus, hypothyroidism or decompensated thoracic deformity. To confirm the diagnosis of silent asthma were performed in all patients, clinical evaluation and pharmacodynamic test with spirometry. The weight status was through the Body Mass Index, recommended by the World Health Organization (WHO).  Results: The weight status showed 32 patients with normal weight, 39 were overweight and 85 obese patients. The incidence of silent asthma in a patient with normal weight was 1% (01 patients), overweight 7.89% (3 patients), grade I obese 26.32% (10 patients), obese grade II 15.79% (6 patients) and grade III obesity 47.37% (18 patients). Conclusion: The results of this study showed that there is a positive association between body mass index with high occurrence silent asthma.